Recent Updates — TLPPF
Telix Pharmaceuticals Limited is convening a general meeting on December 1, 2026, to seek shareholder approval for its proposed acquisition of 100% of ITM Isotope Technologies Munich SE. The transaction involves an upfront consideration valued at US$1.65 billion and contingent milestone payments of up to US$700 million based on regulatory approvals and commercial sales of ITM-11. Telix will issue shares as part of the consideration, requiring approval for maximum upfront, regulatory, and future sales milestone share issuances under ASX Listing Rule 7.1. The Board also seeks approval to elect Dr. Andrew Cavey and Dr. Barbara Weber as new directors effective upon closing. Telix Pharmaceuticals Limited is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer treatment.
Telix Pharmaceuticals received FDA Fast Track designation for its BiPASS program, which evaluates 68Ga-PSMA-PET imaging combined with MRI to detect prostate cancer prior to biopsy. This regulatory milestone facilitates more frequent engagement with the FDA and may enable expedited review of a planned New Drug Application (NDA). The company recently completed enrollment in the Phase 3 BiPASS study using its proprietary agents Illuccix and Gozellix, aiming to reduce unnecessary invasive procedures by improving diagnostic confidence. Telix Pharmaceuticals is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer diagnosis and treatment.
Telix Pharmaceuticals Limited announced a strategic merger with ITM Isotope Technologies Munich SE to create a vertically integrated radiopharmaceutical powerhouse. The transaction involves an upfront consideration of US$1.65 billion on a cash-free/debt-free basis, comprising approximately US$1.25 billion in Telix shares issued at US$11.841 per share and the assumption of US$302 million in net debt. Up to US$700 million in additional contingent consideration is tied to regulatory approvals and sales milestones for ITM-11, a late-stage therapeutic candidate for neuroendocrine tumors. The combined entity expects pro forma 2026 revenue exceeding US$1.3 billion. Telix Pharmaceuticals Limited operates in the radiopharmaceutical industry, developing targeted theranostics for cancer diagnosis and treatment.
On September 14, 2026, the U.S. Food and Drug Administration approved Telix Pharmaceuticals' New Drug Application for Pixclara (floretyrosine F 18), marking it as the first FDA-approved PET imaging drug for glioma. This approval addresses a significant unmet need by enabling physicians to differentiate recurrent or progressive brain cancer from treatment-related changes in adults and pediatric patients, aligning with international clinical guidelines such as NCCN. The regulatory milestone expands Telix’s precision medicine portfolio and reinforces its leadership in theranostics. Telix Pharmaceuticals Limited is a commercial-stage global radiopharmaceutical company advancing targeted theranostics to improve outcomes for people with cancer.
Telix Pharmaceuticals completed enrollment in its Phase 3 BiPASS study on September 2, 2026, recruiting 350 patients to evaluate the diagnostic performance of Illuccix and Gozellix for prostate cancer imaging prior to biopsy. The company also aligned with the FDA on a New Drug Application pathway that could support reimbursement and broaden access to its PSMA-PET agents. Telix Pharmaceuticals is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer diagnosis and treatment.
Telix Pharmaceuticals appointed David Gill as Chair of the Board effective September 1, 2026. Mr. Gill joined the company as a Non-Executive Director in May 2026 and succeeds Dr. Mark Nelson, who served as interim Chair and will remain on the Board. Telix is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer treatment.